HER-2-targeted nanoparticle-affibody bioconjugates for cancer therapy (Q36448817)

14 August 2017

HER-2-targeted nanoparticle-affibody bioconjugates for cancer therapy (English)

1 reference

14 August 2017

0 references

Frank Alexis

1

1 reference

14 August 2017

Pamela Basto

2

1 reference

14 August 2017

Etgar Levy-Nissenbaum

3

1 reference

14 August 2017

Aleksandar F Radovic-Moreno

4

1 reference

14 August 2017

Liangfang Zhang

5

1 reference

14 August 2017

Eric Pridgen

6

1 reference

14 August 2017

Andrew Z Wang

7

1 reference

14 August 2017

Shawn L Marein

8

1 reference

14 August 2017

Katrina Westerhof

9

1 reference

14 August 2017

Linda K Molnar

10

1 reference

14 August 2017

Omid C Farokhzad

11

1 reference

14 August 2017

1 December 2008

1 reference

14 August 2017

1 reference

14 August 2017

3

1 reference

14 August 2017

12

1 reference

14 August 2017

1839-1843

1 reference

Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers.

14 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3515656

New frontiers in nanotechnology for cancer treatment

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3515656

Biodegradable, polymeric nanoparticle delivery systems for cancer therapy

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3515656

Effect of liposome characteristics and dose on the pharmacokinetics of liposomes coated with poly(amino acid)s

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3515656

Co-delivery of hydrophobic and hydrophilic drugs from nanoparticle-aptamer bioconjugates

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3515656

Sheddable coatings for long-circulating nanoparticles

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3515656

Phage display selection of Affibody molecules with specific binding to the extracellular domain of the epidermal growth factor receptor.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3515656

Affibody molecules: potential for in vivo imaging of molecular targets for cancer therapy

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3515656

Nanomedicine: developing smarter therapeutic and diagnostic modalities

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3515656

Antitumor effect of trastuzumab for pancreatic cancer with high HER-2 expression and enhancement of effect by combined therapy with gemcitabine

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3515656

Tumor imaging using a picomolar affinity HER2 binding affibody molecule

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3515656

Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3515656

Preclinical efficacy of the camptothecin-polymer conjugate IT-101 in multiple cancer models

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3515656

Multi-functional polymeric nanoparticles for tumour-targeted drug delivery

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3515656

Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3515656

Nanoparticles in cancer therapy and diagnosis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3515656

A phase I dose-escalating study of DaunoXome, liposomal daunorubicin, in metastatic breast cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3515656

RGD and other recognition sequences for integrins

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3515656

Drug-monoclonal antibody conjugates for cancer therapy: potentials and limitations

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3515656

Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3515656

Drug delivery. Drugs on target

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3515656

Requirements for the internalization of a murine monoclonal antibody directed against the HER-2/neu gene product c-erbB-2

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3515656

Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3515656

HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3515656

Effect of PEO surface density on long-circulating PLA-PEO nanoparticles which are very low complement activators

21 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19012296

12 December 2020

inferred from PubMed ID database lookup

Doxil in breast cancer

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19012296

12 December 2020

inferred from PubMed ID database lookup

Synthetic affibody molecules: a novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19012296

12 December 2020

inferred from PubMed ID database lookup

Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer.

1 reference

Crossref

https://api.crossref.org/works/10.1002%2FCMDC.200800122

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1002/CMDC.200800122

1 reference

14 August 2017

1 reference

14 August 2017

1 reference